{
    "clinical_study": {
        "@rank": "80425", 
        "arm_group": {
            "arm_group_label": "GS-1101", 
            "arm_group_type": "Experimental", 
            "description": "GS-1101 (oral; 150 mg BID)"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the effect of GS-1101 on the onset, magnitude, and\n      duration of tumor control"
        }, 
        "brief_title": "A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Lymphocytic Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Leukemia, Lymphoid"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a Phase 2, multicenter, single-arm, controlled, clinical trial evaluating the\n      efficacy and safety of the phosphatidylinositol 3-kinase delta (PI3K-delta) inhibitor\n      GS-1101 (CAL-101) as therapy for previously treated chronic lymphocytic leukemia.\n\n      This clinical trial (Study GS-US-312-0120) is a single-arm in which compliant subjects from\n      GS US-312-0119 -Arm B who experience progression of CLL while receiving single-agent\n      ofatumumab therapy are potentially eligible to receive single-agent, open-label GS 1101\n      therapy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Participation in Study GS-US-312-0119\n\n          -  Occurrence of confirmed progression of CLL while receiving single-agent ofatumumab in\n             Study GS US 312 0119.\n\n          -  Permanent cessation of Study GS-US-312-0119 (single-agent ofatumumab) and no\n             intervening or continuing therapy (including radiotherapy, chemotherapy,\n             immunotherapy, or investigational therapy) for the treatment of CLL.\n\n          -  The time from permanent cessation of single-agent ofatumumab on Study GS-US-312-0119\n             and the initiation of GS 1101 on Study GS-US-312-0120 is no more than 12 weeks."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 3, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01659047", 
            "org_study_id": "GS-US-312-0120"
        }, 
        "intervention": {
            "arm_group_label": "GS-1101", 
            "description": "150 mg taken twice daily by mouth", 
            "intervention_name": "GS-1101", 
            "intervention_type": "Drug", 
            "other_name": "CAL-101"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Chronic Lymphocytic Leukemia", 
            "CLL", 
            "CAL-101", 
            "Ofatumumab"
        ], 
        "lastchanged_date": "September 6, 2012", 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia", 
        "overall_official": {
            "affiliation": "Gilead Sciences", 
            "last_name": "Langdon Miller, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "18 mon"
            }, 
            {
                "description": "Health-related quality-of-life questionnaire", 
                "measure": "Patient Well-Being", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "Disease-related Biomarkers", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "description": "Evaluation of plasma concentrations at peak (Cmax) and trough (Cmin)", 
                "measure": "Pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Incidence of Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "Health Resource Utilization", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01659047"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Gilead Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}